Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Emphysema Market Size Changed, over the years?

In recent times, the emphysema market size has experienced robust growth. The prediction is that it will rise from $4.74 billion in 2024 to about $4.99 billion in 2025, at a compound annual growth rate (CAGR) of 5.2%. Factors contributing to this growth during the historic period include a surge in respiratory diseases, an increase in the elderly population, a rise in smoking habits, escalating air pollution, enhanced government initiatives, and growth in the number of tobacco smokers.

How Much Will the Emphysema Market Be Worth in 2029?

Anticipations are high for the emphysema market size to experience consistent expansion in the coming years. The predictions suggest a growth to $6.05 billion by 2029, with a compound annual growth rate (CAGR) of 4.9%. Numerous factors are contributing to this growth expected within the forecast period, such as increased spending in healthcare, escalating environmental pollution, amplified demand for medical devices used for diagnosis, rising vehicle traffic, and an expanding preference for minimally invasive procedures. The forecast period will also witness certain key trends: the introduction of new inhalation devices, formation of strategic partnerships, customization in medicines, implementation of telemedicine, innovative inhalation therapies, and breakthroughs in medical technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21956&type=smp

Which is the Largest Company in the Emphysema Market?

Major companies operating in the emphysema market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., Olympus Corporation, ResMed Inc., Chiesi Farmaceutici S.p.A., University of Chicago Medicine (UChicago Medicine), Hikma Pharmaceuticals PLC, United Therapeutics Corporation, VIDA Diagnostics Inc., Kamada Limited, Pulmonx Corporation, Mereo BioPharma Group PLC, Uptake Medical Corporation, Verona Pharma PLC.

What Are the Main Market Drivers in the Emphysema Industry?

The rise in respiratory infections is anticipated to fuel the growth of the emphysema market. A respiratory infection, which influences the sinuses, throat, airways, and lungs, is increasing due to factors such as pollution, climate change, antimicrobial resistance, urbanization, and adaptive pathogens. These infections can hasten the progression of emphysema by triggering inflammation, tissue injury, and elevated airway blockage, thus deteriorating lung function. For instance, the Centers for Disease Control and Prevention, a U.S.-based government agency, revealed in November 2024 that there was a 15.6% increase in tuberculosis (TB) cases in the U.S. in 2023, rising from 8,332 in 2022 to 9,633, with the incidence rate growing 15.0% from 2.5 to 2.9 per 100,000 individuals. Hence, the mounting occurrence of respiratory infections is propelling the emphysema market’s expansion.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21956&type=smp

How Is the Emphysema Market Segments Structured?

The emphysema market covered in this report is segmented –

1) By Type: Centrilobular, Panlobular

2) By Treatment: Medication, Therapy, Surgery, Other Treatments

3) By Diagnosis: Imaging Test, Lung Function Test, Other Diagnosis

4) By Complications: Chest Infections, Collapsed Lung, Heart Problems, Lungs Hole, Other Complications

5) By End-user: Hospitals And Clinics, Surgical Center, Other End-users

Subsegments:

1) By Centrilobular: Mild Centrilobular Emphysema, Moderate Centrilobular Emphysema, Severe Centrilobular Emphysema

2) By Panlobular: Mild Panlobular Emphysema, Moderate Panlobular Emphysema, Severe Panlobular Emphysema

What Strategic Trends Are Transforming the Emphysema Market?

The emphysema market’s key players are concentrating on medical breakthroughs, such as the inhalation of dual inhibitors of phosphodiesterase 3 and 4, to provide advanced treatments improving lung function, reducing inflammation, and enhancing the overall disease management, thus promoting enhanced respiratory health and quality of life. An inhaled dual inhibitor of phosphodiesterase 3 and 4 is a drug that targets and inhibits both phosphodiesterase enzymes in the lungs, assisting in airways relaxation and inflammation reduction, thereby improving breathing in conditions like chronic obstructive pulmonary disease. For example, in June 2024, Verona Pharma plc, a pharma company based in the UK, introduced Ohtuvayre (ensifentrine), marking it as the first inhaled dual PDE3 and PDE4 inhibitor approved by the Food and Drug Administration, a federal agency of the United States. This drug, intended for maintenance treatment of chronic obstructive pulmonary conditions like emphysema, is the first new inhaled treatment in over two decades. The drug, amalgamating bronchodilator and anti-inflammatory effects, will be accessible through specialty pharmacies.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report

Which Global Regions Offer the Highest Growth in the Emphysema Market?

North America was the largest region in the emphysema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emphysema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21956

This Report Delivers Insight On:

1. How big is the emphysema market, and how is it changing globally?

2. Who are the major companies in the emphysema market, and how are they performing?

3. What are the key opportunities and risks in the emphysema market right now?

4. Which products or customer segments are growing the most in the emphysema market?

5. What factors are helping or slowing down the growth of the emphysema market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model